Last updated on February 2018

Mycophenolic Acid Pharmacokinetics and Pharmacogenomics in Lupus Nephritis

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lupus Nephritis
  • Age: Between 18 - 80 Years
  • Gender: Male or Female

Inclusion Criteria:

  1. Patients with recent active LN (biopsy-proven Class III/IV+/-V LN according to the ISN/RPS 2003 classifications within 3 months, with proteinuria >0.5 g/day and/or active urinary sediments) who receive corticosteroids and MMF (1g bd for 6 months) as induction treatment.
  2. LN patients in remission (defined as proteinuria <0.5 g/day with inactive urinary sediment, prednisolone <10 mg/day) and on stable MMF maintenance (dose unchanged within the previous 3 months).

Exclusion Criteria:

  1. Patients who receive enteric-coated mycophenolic acid (myfortic).
  2. Patients who receive concomitant calcineurin inhibitors (e.g. cyclosporine or tacrolimus) other than corticosteroids and MMF.
  3. Patients who receive concomitant medications which affect the MPA pharmacokinetics such as cholestyramine, acyclovir, and rifampicin.
  4. Patients who are pregnant or lactating.
  5. Patients with gastric emptying disorders
  6. Patients with hepatic or biliary diseases

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.